Ultragenyx Pharmaceutical

Ultragenyx is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. It is creating an improved model for successful rare disease drug development that increases efficiency and effectiveness by changing the way the process is organized and conducted. The Company believes that it can deliver significant value to its patients by building a diverse and high quality pipeline of rare disease therapeutics and efficiently transforming good science into great medicine. 

Company Growth (employees)
Novato, US
Size (employees)
376 (est)+31%
Ultragenyx Pharmaceutical was founded in 2010 and is headquartered in Novato, US

Ultragenyx Pharmaceutical Office Locations

Ultragenyx Pharmaceutical has an office in Novato
Novato, US (HQ)
60 Leveroni Ct

Ultragenyx Pharmaceutical Data and Metrics

Ultragenyx Pharmaceutical Financial Metrics

Ultragenyx Pharmaceutical's revenue was reported to be $133 k in FY, 2016
$, USD

Revenue (FY, 2016)

133 k

Net income (FY, 2016)

(245.9 m)

EBIT (FY, 2016)

(248 m)

Market capitalization (06-Jun-2017)

2.4 b

Closing share price (06-Jun-2017)


Cash (31-Dec-2016)

161.1 m
Ultragenyx Pharmaceutical's current market capitalization is $2.4 b.
$, USDFY, 2014FY, 2015FY, 2016


133 k

R&D expense

46 m114.7 m183.2 m

General and administrative expense

10.8 m33 m64.9 m

Operating expense total

56.8 m147.7 m248.1 m


(56.8 m)(147.7 m)(248 m)

EBIT margin, %


Interest income

608 k2.3 m3.8 m

Pre tax profit

(245.8 m)

Income tax expense

(35 k)

Net Income

(59.8 m)(145.6 m)(245.9 m)
$, USDFY, 2014FY, 2015FY, 2016


24.3 m93.6 m161.1 m


5.9 m13.1 m20.1 m

Current Assets

193.4 m450.2 m401.7 m


3 m7.4 m17.1 m

Total Assets

198 m559.6 m540.6 m

Accounts Payable

4.9 m2.9 m5.4 m

Current Liabilities

12.5 m27.9 m60.3 m

Additional Paid-in Capital

324.1 m816.6 m1 b

Retained Earnings

(139 m)(284.7 m)(530.5 m)

Total Equity

531.1 m474 m

Financial Leverage

1.1 x1.1 x
$, USDFY, 2014FY, 2015FY, 2016

Net Income

(59.8 m)(145.6 m)(245.9 m)

Depreciation and Amortization

684 k1.4 m3.4 m


(4.1 m)(7.1 m)(7.1 m)

Accounts Payable

3.2 m(2 m)2.5 m

Cash From Operating Activities

(44.6 m)(106 m)(161 m)

Purchases of PP&E

(2.1 m)(5 m)(10.2 m)

Cash From Investing Activities

(123.4 m)(292.4 m)89.9 m

Cash From Financing Activities

185 m467.6 m138.7 m
$, USDY, 2016



Financial Leverage

1.1 x

Ultragenyx Pharmaceutical Market Value History

Ultragenyx Pharmaceutical Company Life and Culture

You may also be interested in